Table 5.

The antitumor activity of some synthesized pyrimidine compounds 10 and 12 against the breast cancer cell line MCF-7 as compared to cisplatin standard antitumor as detected using MTT assay.

Conc. (µg/ml)	Compounds
	10		12
	Viability (%)	Inhibition (%)	Viability (%)	Inhibition (%)
500.0	17.85 ± 1.39	82.15	35.79 ± 2.37	64.21
250.0	38.71 ± 2.05	61.29	80.62 ± 1.46	19.38
125.0	64.56 ± 1.42	35.44	98.96 ± 0.42	1.04
62.5	88.07 ± 0.69	11.93	100	0
31.25	98.12 ± 0.44	1.88	100	0
15.6	100	0	100	0
7.8	100	0	100	0
3.9	100	0	100	0
2.0	100	0	100	0
1.0	100	0	100	0
0.0	100	0	100	0
IC50 (µg/ml)	195.40 ± 6.93		420.75 ± 17.28